Literature DB >> 18382738

Confronting the scientific obstacles to global control of tuberculosis.

Douglas B Young1, Mark D Perkins, Ken Duncan, Clifton E Barry.   

Abstract

Tuberculosis (TB) is a major threat to global health, recently exacerbated by the emergence of highly drug-resistant forms of the disease-causing pathogen and synergy with HIV/AIDS. In 2006, the Stop TB Partnership published "The global plan to stop TB: 2006--2015," which set out a vision of halving the prevalence of and mortality caused by the disease by 2015, followed by eliminating the disease as a public health problem by 2050. This vision depends on the development of improved diagnostics, simpler treatment, and more effective vaccination. Recently, active translational research pipelines directed toward each of these goals have been established, but improved understanding of the fundamental biology of this complex disease will prove to be the key to radical advances in TB control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382738      PMCID: PMC2276805          DOI: 10.1172/JCI34614

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  115 in total

1.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.

Authors:  Leander Grode; Peter Seiler; Sven Baumann; Jürgen Hess; Volker Brinkmann; Ali Nasser Eddine; Peggy Mann; Christian Goosmann; Silke Bandermann; Debbie Smith; Gregory J Bancroft; Jean-Marc Reyrat; Dick van Soolingen; Bärbel Raupach; Stefan H E Kaufmann
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

2.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

Review 3.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

4.  Contacts of cases of active pulmonary tuberculosis.

Authors:  S Grzybowski; G D Barnett; K Styblo
Journal:  Bull Int Union Tuberc       Date:  1975

Review 5.  High-throughput screening assays for the identification of chemical probes.

Authors:  James Inglese; Ronald L Johnson; Anton Simeonov; Menghang Xia; Wei Zheng; Christopher P Austin; Douglas S Auld
Journal:  Nat Chem Biol       Date:  2007-08       Impact factor: 15.040

Review 6.  In search of new cures for tuberculosis.

Authors:  Marina Protopopova; Elena Bogatcheva; Boris Nikonenko; Sam Hundert; Leo Einck; Carol A Nacy
Journal:  Med Chem       Date:  2007-05       Impact factor: 2.745

7.  Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine.

Authors:  B Hamasur; J Bruchfeld; M Haile; A Pawlowski; B Bjorvatn; G Källenius; S B Svenson
Journal:  J Microbiol Methods       Date:  2001-05       Impact factor: 2.363

8.  Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

Authors:  Else Marie Agger; Ida Rosenkrands; Anja Weinreich Olsen; Graham Hatch; Ann Williams; Constantia Kritsch; Karen Lingnau; Alexander von Gabain; Claire Swetman Andersen; Karen Smith Korsholm; Peter Andersen
Journal:  Vaccine       Date:  2006-04-17       Impact factor: 3.641

9.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Authors:  Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

10.  Genes required for mycobacterial growth defined by high density mutagenesis.

Authors:  Christopher M Sassetti; Dana H Boyd; Eric J Rubin
Journal:  Mol Microbiol       Date:  2003-04       Impact factor: 3.501

View more
  114 in total

1.  Association of genetic polymorphisms in the IL12-IFNG pathway with susceptibility to and prognosis of pulmonary tuberculosis in a Chinese population.

Authors:  J Wang; S Tang; H Shen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-11       Impact factor: 3.267

2.  Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice.

Authors:  Neeraj Dhar; John D McKinney
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

3.  Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry.

Authors:  M Lisa Manier; Michelle L Reyzer; Anne Goh; Veronique Dartois; Laura E Via; Clifton E Barry; Richard M Caprioli
Journal:  J Am Soc Mass Spectrom       Date:  2011-05-13       Impact factor: 3.109

4.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

5.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

Review 6.  Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis.

Authors:  Karen R Steingart; Nandini Dendukuri; Megan Henry; Ian Schiller; Payam Nahid; Philip C Hopewell; Andrew Ramsay; Madhukar Pai; Suman Laal
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

Review 7.  Unfolding the relationship between secreted molecular chaperones and macrophage activation states.

Authors:  Brian Henderson; Samantha Henderson
Journal:  Cell Stress Chaperones       Date:  2008-10-29       Impact factor: 3.667

8.  A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.

Authors:  Jee-Hyun Kim; Kathryn M O'Brien; Ritu Sharma; Helena I M Boshoff; German Rehren; Sumit Chakraborty; Joshua B Wallach; Mercedes Monteleone; Daniel J Wilson; Courtney C Aldrich; Clifton E Barry; Kyu Y Rhee; Sabine Ehrt; Dirk Schnappinger
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

9.  Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.

Authors:  Vadim Makarov; Giulia Manina; Katarina Mikusova; Ute Möllmann; Olga Ryabova; Brigitte Saint-Joanis; Neeraj Dhar; Maria Rosalia Pasca; Silvia Buroni; Anna Paola Lucarelli; Anna Milano; Edda De Rossi; Martina Belanova; Adela Bobovska; Petronela Dianiskova; Jana Kordulakova; Claudia Sala; Elizabeth Fullam; Patricia Schneider; John D McKinney; Priscille Brodin; Thierry Christophe; Simon Waddell; Philip Butcher; Jakob Albrethsen; Ida Rosenkrands; Roland Brosch; Vrinda Nandi; Sowmya Bharath; Sheshagiri Gaonkar; Radha K Shandil; Venkataraman Balasubramanian; Tanjore Balganesh; Sandeep Tyagi; Jacques Grosset; Giovanna Riccardi; Stewart T Cole
Journal:  Science       Date:  2009-03-19       Impact factor: 47.728

10.  BacA, an ABC transporter involved in maintenance of chronic murine infections with Mycobacterium tuberculosis.

Authors:  Pilar Domenech; Hajime Kobayashi; Kristin LeVier; Graham C Walker; Clifton E Barry
Journal:  J Bacteriol       Date:  2008-11-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.